Bortezomib: Difference between revisions
From IDWiki
(Created page with "* Used for multiple myeloma and mantle cell lymphoma Category:Medications Category:Hematology Category:Oncology") |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
| + | * [[Proteasome inhibitor]] |
||
* Used for [[multiple myeloma]] and [[mantle cell lymphoma]] |
* Used for [[multiple myeloma]] and [[mantle cell lymphoma]] |
||
| + | * Effects on immune system include neutropenia, lymphopenia (particularly CD8 T-cells and NK cells), dendritic cell inhibition, altered cytokine secretion |
||
| + | * Increases risk of [[HSV]] and [[VZV]]; often used with concurrent [[dexamethasone]] |
||
[[Category:Medications]] |
[[Category:Medications]] |
||
Latest revision as of 13:05, 14 November 2022
- Proteasome inhibitor
- Used for multiple myeloma and mantle cell lymphoma
- Effects on immune system include neutropenia, lymphopenia (particularly CD8 T-cells and NK cells), dendritic cell inhibition, altered cytokine secretion
- Increases risk of HSV and VZV; often used with concurrent dexamethasone
